Enteris BioPharma offers innovative formulation solutions built around its proprietary oral delivery technology platform – Peptelligence®. Since its founding in 2013, Enteris BioPharma has advanced multiple internal and external programs leveraging its Peptelligence® platform. The technology has been developed and proven effective to enable the safe delivery of peptide-based therapeutics and other molecules with low oral bioavailability.

PEPTELLIGENCE®

Enteris BioPharma offers Intelligent Solutions for Oral Drug Delivery of peptides and BCS Class II, Class III and Class IV compounds in an enteric-coated tablet.

LEARN MORE

PIPELINE

Enteris BioPharma internal pipeline of products for women’s health are being evaluated and include Ovarest® for endometriosis and Tobrate™ for uUTIs.

LEARN MORE

PARTNERING

Enteris BioPharma builds long-term relationships, with proven clinical stage biopharmaceutical oral peptide drug delivery solutions in novel formulations.

LEARN MORE

ABOUT US

Enteris BioPharma is a privately held, clinical stage biopharmaceutical company in NJ with formulation solutions via proprietary oral peptide delivery technologies.

LEARN MORE

NEWS & EVENTS

Enteris, KeyBioscience to Develop Solutions for Metabolic Disorders Ferring, Enteris to Develop Oral Peptide Therapeutic

LEARN MORE
 
 

CONTACT US